Back to search results

Ablation-Index Guided Ventricular Tachycardia Ablation for Ischemic Cardiomyopathy

This study is looking at a procedure called ventricular tachycardia ablation, which uses heat to treat a fast, irregular heartbeat (ventricular tachycardia) in people with heart damage from a previous heart attack (ischemic cardiomyopathy). Researchers are comparing two ways to perform this procedure: with and without guidance from something called an Ablation Index (AI). The AI helps doctors better understand how well the heat treatment is working. The main goal is to see if using AI guidance can reduce the time it takes to perform the ablation. You might be able to join if you are at least 18 years old, have ischemic cardiomyopathy, and have documented sustained ventricular tachycardia. The study aims to enroll 100 participants, but its current recruitment status is unclear.

Study design
This is an interventional study comparing two different procedures for ventricular tachycardia ablation. It plans to enroll 100 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured during the procedure (intra-procedural).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06138873

Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy

Recruiting
NAAges 18+InterventionalTreatment
Rush University Medical Center
~100 participants
Updated 2025-09-22 on ClinicalTrials.gov
What's tested:Ablation-index guided ventricular tachycardia ablationVentricular tachycardia ablation with no AI-guidance

At a glance

Recruiting sites
1 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage reduction in ablation time between the groups with/without AI guidance
Measured over intra-procedural

Conditions

Ventricular Tachycardia
Ischemic Cardiomyopathy

Explore related trials

Generalized ischemic myocardial dysfunctionVentricular Tachycardia

Where it's being run

5 sites across 5 states
Illinois1
Massachusetts1
Michigan1
Minnesota1
South Carolina1

Study leadership

  • Alexander Mazur, MD · PRINCIPAL_INVESTIGATOR · Rush University Medical Center

Who to contact

Alexander Mazur, MD
[email protected]
312-942-5020
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient ≥ 18 y.o.
Structural Heart Disease: Ischemic Cardiomyopathy
Sustained Scar-related Monomorphic Ventricular Tachycardia documented by ECG or CIED interrogation

Exclusion

If clinical ventricular arrhythmia is predominantly PVCs, supraventricular tachycardia, or ventricular fibrillation
Myocardial infarction or cardiac surgery within 6 months
Severe mitral regurgitation
Stroke or TIA within 6 months
Prior VT substrate ablation in the previous 6 months
NYHA functional class IV
Non-ischemic VT substrate

What this trial measures

  • Percentage reduction in ablation time between the groups with/without AI guidanceintra-procedural

    Percentage of reduction in ablation time in seconds, with ablation time defined as the total radiofrequency delivery time delivered during the VT ablation procedure. Total ablation time is automatically recorded by the Carto System Software and will be subsequently extracted as part of a raw unedited data file for unbiased endpoint evaluation.